| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 82,031 | |||
| Short-term investments | 20,161 | |||
| R&d benefit receivable | 22,152 | |||
| Other current assets | 9,260 | |||
| Trade receivables | 28 | |||
| Total current assets | 133,632 | |||
| Property, plant and equipment | 1,655 | |||
| Operating lease right-of-use asset | 192 | |||
| Goodwill | 10,612 | |||
| Other intangible assets | 300 | |||
| Other long-term assets | 399 | |||
| Total assets | 146,790 | |||
| Contract liabilities | 301 | |||
| Trade and other payables | 16,993 | |||
| Operating lease liabilities, current | 85 | |||
| Total current liabilities | 17,379 | |||
| Contract liabilities | 55,251 | |||
| Operating lease liabilities | 97 | |||
| Total liabilities | 72,727 | |||
| Ordinary shares - par value 0.05 per share 141,701,848 shares issued at september 30, 2025 (december 31, 2024 141,674,074) | 10,290 | |||
| Additional paid-in capital | 617,648 | |||
| Accumulated deficit | -550,802 | |||
| Accumulated other comprehensive loss | -3,073 | |||
| Total shareholders' equity | 74,063 | |||
| Total liabilities and shareholders' equity | 146,790 | |||
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)